• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Inventiva S.A.

    11/19/25 5:10:30 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IVA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)


    Inventiva S.A.

    (Name of Issuer)


    Ordinary Shares, nominal value (euro)0.01 per share

    (Title of Class of Securities)


    46124U107

    (CUSIP Number)


    JAMES KRATKY
    BVF PARTNERS L.P., 44 Montgomery St., 40th Floor
    San Francisco, CA, 94104
    415-525-8830

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    11/17/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    46124U107


    1 Name of reporting person

    BIOTECHNOLOGY VALUE FUND L P
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    5,654,825.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    5,654,825.00
    11Aggregate amount beneficially owned by each reporting person

    5,654,825.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.9 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    46124U107


    1 Name of reporting person

    BVF I GP LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    5,654,825.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    5,654,825.00
    11Aggregate amount beneficially owned by each reporting person

    5,654,825.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.9 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    46124U107


    1 Name of reporting person

    BIOTECHNOLOGY VALUE FUND II LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,321,861.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,321,861.00
    11Aggregate amount beneficially owned by each reporting person

    3,321,861.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.7 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    46124U107


    1 Name of reporting person

    BVF II GP LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,321,861.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,321,861.00
    11Aggregate amount beneficially owned by each reporting person

    3,321,861.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.7 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    46124U107


    1 Name of reporting person

    Biotechnology Value Trading Fund OS LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    397,086.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    397,086.00
    11Aggregate amount beneficially owned by each reporting person

    397,086.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.2 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    46124U107


    1 Name of reporting person

    BVF Partners OS Ltd.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    397,086.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    397,086.00
    11Aggregate amount beneficially owned by each reporting person

    397,086.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.2 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP No.
    46124U107


    1 Name of reporting person

    BVF GP HOLDINGS LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    8,976,686.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    8,976,686.00
    11Aggregate amount beneficially owned by each reporting person

    8,976,686.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.7 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    46124U107


    1 Name of reporting person

    BVF PARTNERS L P/IL
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,569,863.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,569,863.00
    11Aggregate amount beneficially owned by each reporting person

    9,569,863.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.99 %
    14Type of Reporting Person (See Instructions)

    IA, PN



    SCHEDULE 13D

    CUSIP No.
    46124U107


    1 Name of reporting person

    BVF INC/IL
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,569,863.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,569,863.00
    11Aggregate amount beneficially owned by each reporting person

    9,569,863.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.99 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP No.
    46124U107


    1 Name of reporting person

    LAMPERT MARK N
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,569,863.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,569,863.00
    11Aggregate amount beneficially owned by each reporting person

    9,569,863.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.99 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Ordinary Shares, nominal value (euro)0.01 per share
    (b)Name of Issuer:

    Inventiva S.A.
    (c)Address of Issuer's Principal Executive Offices:

    50 RUE DE DIJON, DAIX, FRANCE , 21121.
    Item 1 Comment:
    This statement relates to the Ordinary Shares, nominal value (euro)0.01 per share (the "Shares"), of Inventiva S.A., a corporation organized under the laws of France (the "Issuer"), and to American Depositary Shares of the Issuer ("ADSs"), each of which represents one Share. This Amendment No. 6 to the Schedule 13D is being filed due to a change in the percentage of the outstanding number of Shares and ADSs owned by the Reporting Persons solely due to an increase in the number of Shares and/or ADSs outstanding.
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5(a) is hereby amended and restated to read as follows: The aggregate percentage of Shares reported owned by each person named herein is based on a denominator which is the sum of: (i) 145,951,274 Shares outstanding (including Shares underlying ADSs) as of October 20, 2025, which is the total number of Shares outstanding as reported in the Issuer's Press Release issued on October 20, 2025, and (ii) 44,805,193 ADSs issued following the closing of the Issuer's offering (including the underwriters' full exercise of an option to purchase additional ADSs) as disclosed in Exhibit 99.1 to the Issuer's Report of Foreign Issuer on From 6-K filed with the Securities and Exchange Commission on November 17, 2025.
    (b)
    Item 5(b) is hereby amended and restated to read as follows: As of the date hereof, the Reporting Persons and the Partners Managed Account held an aggregate of 10,103,703 T2 PFW-BSAs, exercisable into an aggregate of 19,197,036 Shares. As of the date hereof, the T2 PFW Beneficial Ownership Limitation limits the exercise of the T2 PFWs held by the Reporting Persons and the Partners Managed Account to 1,024,364 Shares underlying the T2 PFWs held by them. The Warrants may not be exercised until the Warrant Exercise Event. As of the date hereof, the Reporting Persons and the Partners Managed Account held an aggregate of 8,231,034 T1 BSAs and 1,872,668 T1 bis BSAs, exercisable into an aggregate of 8,231,034 Shares and 1,872,668 Shares, respectively. As of the date hereof, the T1 BSA Beneficial Ownership Limitation and the T1 bis BSA Beneficial Ownership Limitation prohibits the exercise of all of the T1 BSAs and T1 bis BSAs held by the Reporting Persons and the Partners Managed Account. As of the date hereof, (i) BVF beneficially owned 5,654,825 Shares, including 451,003 Shares underlying ADSs and 1,024,364 Shares underlying certain T2 PFWs held by it, and excluding (a) 3,974,936 Shares issuable upon the exercise of the T1 BSAs held by it, (b) 979,028 Shares issuable upon the exercise of the T1 bis BSAs held by it and (c) 9,197,858 Shares issuable upon the exercise of certain T2 PFW-BSAs held by it, representing percentage ownership of approximately 2.9% of the Shares outstanding, (ii) BVF2 beneficially owned 3,321,861 Shares, including 234,997 Shares underlying ADSs and excluding (a) 3,640,567 Shares issuable upon the exercise of the T1 BSAs held by it, (b) 767,394 Shares issuable upon the exercise of the T1 bis BSAs held by it and (c) 7,161,058 Shares issuable upon the exercise of the T2 PFW-BSAs held by it, representing percentage ownership of approximately 1.7% of the Shares outstanding, (iii) Trading Fund OS beneficially owned 397,086 Shares, including 40 Shares underlying ADSs and excluding (a) 470,954 Shares issuable upon the exercise of the T1 BSAs held by it, (b) 105,296 Shares issuable upon the exercise of the T1 bis BSAs held by it and (c) 1,307,094 Shares issuable upon the exercise of the T2 PFW-BSAs held by it, representing percentage ownership of less than 1% of the Shares outstanding, and (iv) 196,091 Shares were held in the Partners Managed Account, excluding (a) 144,577 Shares issuable upon the exercise of the T1 BSAs held in the Partners Managed Account, (b) 20,950 Shares issuable upon the exercise of the T1 bis BSAs held in the Partners Managed Account and (c) 506,662 Shares issuable upon the exercise of the T2 PFW-BSAs held by it, representing percentage ownership of less than 1% of the Shares outstanding. BVF GP, as the general partner of BVF, may be deemed to beneficially own the 5,654,825 Shares beneficially owned by BVF, representing percentage ownership of approximately 2.9% of the Shares outstanding. BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 3,321,861 Shares beneficially owned by BVF2, representing percentage ownership of approximately 1.7% of the Shares outstanding. Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 397,086 Shares beneficially owned by Trading Fund OS, representing percentage ownership of less than 1% of the Shares outstanding. BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 8,976,686 Shares beneficially owned in the aggregate by BVF and BVF2, representing percentage ownership of approximately 4.7% of the Shares outstanding. Partners, as the investment manager of BVF, BVF2, Trading Fund OS and the Partners Managed Account and the sole member of Partners OS, may be deemed to beneficially own the 9,569,863 Shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and held in the Partners Managed Account, representing percentage ownership of approximately 4.99% of the Shares outstanding. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 9,569,863 Shares beneficially owned by Partners, representing percentage ownership of approximately 4.99% of the Shares outstanding. Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 9,569,863 Shares beneficially owned by BVF Inc., representing percentage ownership of approximately 4.99% of the Shares outstanding.
    (c)
    Item 5(c) is hereby amended and restated to read as follows: The Reporting Persons have not entered into any transactions in the securities of the Issuer during the past sixty days.
    (e)
    As of the close of business on November 17, 2025, the Reporting Persons ceased to beneficially own more than 5% of the outstanding Shares and/or ADSs.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BIOTECHNOLOGY VALUE FUND L P
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:11/19/2025
     
    BVF I GP LLC
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:11/19/2025
     
    BIOTECHNOLOGY VALUE FUND II LP
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:11/19/2025
     
    BVF II GP LLC
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:11/19/2025
     
    Biotechnology Value Trading Fund OS LP
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:11/19/2025
     
    BVF Partners OS Ltd.
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:11/19/2025
     
    BVF GP HOLDINGS LLC
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:11/19/2025
     
    BVF PARTNERS L P/IL
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:11/19/2025
     
    BVF INC/IL
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:11/19/2025
     
    LAMPERT MARK N
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert
    Date:11/19/2025
    Get the next $IVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IVA

    DatePrice TargetRatingAnalyst
    11/6/2025$13.00Outperform
    Wolfe Research
    9/3/2025$20.00Buy
    H.C. Wainwright
    8/27/2025$26.00Overweight
    Piper Sandler
    2/21/2025$10.00Buy
    TD Cowen
    11/12/2024$3.00Neutral
    UBS
    10/27/2023$12.00Buy
    Canaccord Genuity
    5/31/2023$11.00Buy
    ROTH MKM
    5/19/2023Sell → Buy
    Societe Generale
    More analyst ratings

    $IVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inventiva reports 2025 Third Quarter Financial Information¹

    Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4.5 million for the first nine months of 2025.Cash runway expected until the end of the first quarter of 20273, including net proceeds from the November 2025 public offering. Daix (France), New York City, (New York, United States), November 21, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported its cash position as of September 30, 2025 and its revenues for t

    11/21/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva announces full exercise of Underwriters' Option, bringing proceeds of Offering to approximately $172.5M

    Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the underwriters of the previously announced public offering in the United States (the "Offering") of 38,961,038 American Depositary Shares ("ADSs"), each representing one ordinary share of the Company with a nominal value of €0.01, have exercised in full their option (the "Underwriters' Option") to purchase 5,844,155 additional ADSs (the "Additional ADSs").

    11/17/25 2:30:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva announces trading resumption of its ordinary shares on Euronext Paris

    Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 4:30 p.m. (CET).  Trading of the ordinary shares of the Company was halted, at the Company's request, on November 13, 2025, from 9:00 a.m. (CET), in the context of the previously announced public offering by the Company in the United States only of new American Deposita

    11/13/25 10:24:53 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Inventiva with a new price target

    Wolfe Research initiated coverage of Inventiva with a rating of Outperform and set a new price target of $13.00

    11/6/25 8:48:14 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Inventiva with a new price target

    H.C. Wainwright resumed coverage of Inventiva with a rating of Buy and set a new price target of $20.00

    9/3/25 8:38:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Inventiva with a new price target

    Piper Sandler initiated coverage of Inventiva with a rating of Overweight and set a new price target of $26.00

    8/27/25 8:23:53 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Inventiva S.A.

    SCHEDULE 13D/A - Inventiva S.A. (0001756594) (Subject)

    11/19/25 8:52:49 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Inventiva S.A.

    SCHEDULE 13D/A - Inventiva S.A. (0001756594) (Subject)

    11/19/25 5:10:30 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Inventiva S.A.

    6-K - Inventiva S.A. (0001756594) (Filer)

    11/17/25 6:05:06 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Financials

    Live finance-specific insights

    View All

    Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

    Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi

    5/5/25 2:30:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva reports its 2024 full year results and provides a business update

    Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c

    3/26/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

    Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder

    3/19/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Leadership Updates

    Live Leadership Updates

    View All

    Inventiva Appoints Andrew Obenshain as Chief Executive Officer

    Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Andrew Obenshain as Chief Executive Officer ("CEO") of the Company. Mr. Obenshain will also join the Company's Board of Directors. He succeeds Frédéric Cren, the Company's co-founder, who has served as CEO since its inception in 2012. Mr. Cren is also stepping down from the Board of Directors and will work with Mr. Obenshain to ensure a smooth tr

    10/1/25 2:30:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

    Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality AssuranceThese key leadership appointments underscore Inventiva's commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half of 2026 Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic

    7/9/25 4:05:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

    Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by shareholders at the recent Company's Annual General Meeting. Mark Pruzanski, Chairman of Inventiva: "We are thrilled to welcome Renée to the Board at this pivotal moment in Inventiva's journey. Her exceptional track record in our industry speaks for itself and will be

    6/10/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    10/21/24 9:00:40 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    10/21/24 8:54:43 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    7/19/24 4:30:23 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care